Poor Performance Status, Diabetes Mellitus, and Statin use are Risk Factors for Decreased Skeletal Muscle Mass During Nab-paclitaxel Plus Gemcitabine Therapy in Patients with Advanced Pancreatic Cancer.

IF 1.7 4区医学 Q3 GASTROENTEROLOGY & HEPATOLOGY

Pancreas Pub Date : 2025-09-08 DOI:10.1097/MPA.0000000000002565

Kiyotsugu Iede, Terumasa Yamada, Hirotoshi Takayama, Shinsuke Nakashima, Ken Nakata, Shusei Tominaga

引用次数: 0

查看原文本刊更多论文

运动状态不佳、糖尿病和他汀类药物的使用是晚期胰腺癌患者在nab -紫杉醇加吉西他滨治疗期间骨骼肌质量下降的危险因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pancreas 医学-胃肠肝病学

CiteScore

4.70

自引率

3.40%

发文量

289

审稿时长

1 months

期刊介绍： Pancreas provides a central forum for communication of original works involving both basic and clinical research on the exocrine and endocrine pancreas and their interrelationships and consequences in disease states. This multidisciplinary, international journal covers the whole spectrum of basic sciences, etiology, prevention, pathophysiology, diagnosis, and surgical and medical management of pancreatic diseases, including cancer.